GSK RSV Vaccine Arexvy Accepted For EMA Review To Expand Use

GSK plc GSK:

• GSK PLC - GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA

• GSK PLC - GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA

• GSK: REGULATORY DECISION ANTICIPATED H1 2026

• GSK PLC - RSV VACCINE AREXVY ACCEPTED FOR EMA REVIEW TO EXPAND USE

• GSK PLC - REGULATORY DECISION ON GSK'S AREXVY EXPECTED IN H1 2026